Revance Therapeutics (RVNC) 13.25 $RVNC
Revance Appoints Industry Leader Julian S. Gangolli to its Board of Directors
BusinessWire - Tue Jul 05, 7:00AM CDT
Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, has been elected to Revance's Board of Directors and will serve as a member of the Audit Committee, effective July 1, 2016.
AGN: 238.28 (-2.31), RVNC: 13.25 (-0.04)
Synchrony Financial, Wells Fargo and Navistar slip
AP - Tue Jun 14, 3:18PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
MESO: 4.06 (-0.06), MPAA: 27.43 (+0.09), NAV: 12.30 (+0.26), RVNC: 13.25 (-0.04), WFC: 48.08 (+0.29), SYF: 27.67 (+0.36), MSB: 10.78 (+0.11)
Why is Revance Therapeutics (RVNC) Stock Plummeting Today?
Madeleine Johnson - Zacks Investment Research - Tue Jun 14, 10:48AM CDT
On Tuesday, shares of Revance Therapeutics Inc. (RVNC) are plummeting, down over 22% in morning trading after the company reported disappointing results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe lateral canthal lines, or crow's feet.
RVNC: 13.25 (-0.04)
Revance's Lead Candidate Fails in Phase III Crow's Feet Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 10:28AM CDT
Revance Therapeutics' (RVNC) RT001 topical failed to meet the co-primary and other endpoints in a phase III crow's feet study.
PFE: 36.15 (+0.03), RTRX: 18.47 (-0.18), RVNC: 13.25 (-0.04), BMY: 75.39 (+0.11)
Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines
GlobeNewswire - Mon Jun 13, 3:01PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today reported results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe lateral canthal lines, or crow's feet.
RVNC: 13.25 (-0.04)
Revance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio
GlobeNewswire - Thu Jun 02, 5:12PM CDT
- Portfolio covers diverse and novel indications, compositions and formulations -
RVNC: 13.25 (-0.04)
Revance to Participate in Upcoming Investor Conferences
GlobeNewswire - Tue May 31, 3:05PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming investor conferences.
RVNC: 13.25 (-0.04)
Revance reports 1Q loss
Automated Insights - Mon May 09, 5:48PM CDT
NEWARK, Calif. (AP) _ Revance Therapeutics Inc. (RVNC) on Monday reported a loss of $19.9 million in its first quarter.
RVNC: 13.25 (-0.04)
Revance Releases First Quarter 2016 Results
GlobeNewswire - Mon May 09, 3:06PM CDT
- Completes Enrollment in REALISE 1 Phase 3 Trial for RT001 Topical for Crow's Feet Lines -
RVNC: 13.25 (-0.04)
Revance Therapeutics to Release First Quarter 2016 Financial Results Monday, May 9, 2016
GlobeNewswire - Mon Apr 25, 3:01PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the Company will release first quarter 2016 financial results on Monday, May 9, 2016 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business and pipeline update.
RVNC: 13.25 (-0.04)
Revance Therapeutics Expands Leadership Team, Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development
GlobeNewswire - Mon Mar 14, 6:17PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced a key addition to its leadership team with the appointment of Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development, effective immediately. Dr. Rubio will report to Chief Operating Officer Abhay Joshi, and will lead the company's clinical development team, focusing on further accelerating the advancement of Revance's neurotoxin development programs.
RVNC: 13.25 (-0.04)
Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology
GlobeNewswire - Sat Mar 05, 12:45PM CST
- Findings confirm statistically significantly greater duration of effect for RT002 compared to BOTOX(R) Cosmetic -
RVNC: 13.25 (-0.04)
Axillary Hyperhidrosis Pipeline Review H2 2015
M2 - Tue Feb 02, 5:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/w8hlmc/axillary) has announced the addition of the "Axillary Hyperhidrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Axillary Hyperhidrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Axillary Hyperhidrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Axillary Hyperhidrosis Overview - Therapeutics Development - Pipeline Products for Axillary Hyperhidrosis - Overview - Pipeline Products for Axillary Hyperhidrosis - Comparative Analysis - Axillary Hyperhidrosis - Therapeutics under Development by Companies - Axillary Hyperhidrosis - Therapeutics under Investigation by Universities/Institutes - Axillary Hyperhidrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Axillary Hyperhidrosis - Products under Development by Companies - Axillary Hyperhidrosis - Products under Investigation by Universities/Institutes - Axillary Hyperhidrosis - Companies Involved in Therapeutics Development - Allergan Plc - Brickell Biotech, Inc. - Dermira Inc. - GlaxoSmithKline Plc - Revance Therapeutics, Inc. - TheraVida, Inc For more information visit http://www.researchandmarkets.com/research/w8hlmc/axillary
AGN: 238.28 (-2.31), DERM: 30.27 (-0.64), RVNC: 13.25 (-0.04), GSK: 43.52 (+0.14)
Migraine Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tw7v3m/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Migraine Overview - Therapeutics Development - Pipeline Products for Migraine - Overview - Pipeline Products for Migraine - Comparative Analysis - Migraine - Therapeutics under Development by Companies - Migraine - Therapeutics under Investigation by Universities/Institutes - Migraine - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Migraine - Products under Development by Companies - Migraine - Products under Investigation by Universities/Institutes - Migraine - Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - Alder Biopharmaceuticals Inc. - Allergan Plc - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - Corium International, Inc. - D-Pharm Ltd. - Eli Lilly and Company - iCeutica, Inc. - Impel NeuroPharma, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - Promius Pharma, LLC - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited - TheraJect, Inc. - Trevena, Inc. - Trigemina, Inc. - Vertex Pharmaceuticals Incorporated - Zosano Pharma Corporation For more information visit http://www.researchandmarkets.com/research/tw7v3m/migraine
BDSI: 2.51 (-0.07), TRVN: 7.06 (-0.07), VRTX: 90.10 (+1.14), RDHL: 11.75 (+0.45), ZSAN: 1.12 (unch), AMGN: 160.18 (-0.92), LLY: 79.14 (-0.52), ACOR: 25.57 (-0.64), NKTR: 15.07 (+0.15), AGN: 238.28 (-2.31), CORI: 4.00 (unch), ALDR: 26.88 (-0.12), CLCD: 9.00 (-0.03), MRK: 59.34 (-0.01), TEVA: 50.93 (+0.04), RVNC: 13.25 (-0.04), POZN: 5.94 (-0.43)
The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis
Zacks Equity Research - Zacks Investment Research - Fri Jan 08, 8:30AM CST
The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis
LGND: 126.76 (+0.90), AMGN: 160.18 (-0.92), RVNC: 13.25 (-0.04), ABBV: 64.35 (+0.19), EXEL: 8.15 (unch)
Revance Appoints Industry Leader Julian S. Gangolli to its Board of Directors
BusinessWire - Tue Jul 05, 7:00AM CDT
Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, has been elected to Revance's Board of Directors and will serve as a member of the Audit Committee, effective July 1, 2016.
AGN: 238.28 (-2.31), RVNC: 13.25 (-0.04)
Synchrony Financial, Wells Fargo and Navistar slip
AP - Tue Jun 14, 3:18PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
MESO: 4.06 (-0.06), MPAA: 27.43 (+0.09), NAV: 12.30 (+0.26), RVNC: 13.25 (-0.04), WFC: 48.08 (+0.29), SYF: 27.67 (+0.36), MSB: 10.78 (+0.11)
Why is Revance Therapeutics (RVNC) Stock Plummeting Today?
Madeleine Johnson - Zacks Investment Research - Tue Jun 14, 10:48AM CDT
On Tuesday, shares of Revance Therapeutics Inc. (RVNC) are plummeting, down over 22% in morning trading after the company reported disappointing results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe lateral canthal lines, or crow's feet.
RVNC: 13.25 (-0.04)
Revance's Lead Candidate Fails in Phase III Crow's Feet Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 10:28AM CDT
Revance Therapeutics' (RVNC) RT001 topical failed to meet the co-primary and other endpoints in a phase III crow's feet study.
PFE: 36.15 (+0.03), RTRX: 18.47 (-0.18), RVNC: 13.25 (-0.04), BMY: 75.39 (+0.11)
Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines
GlobeNewswire - Mon Jun 13, 3:01PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today reported results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe lateral canthal lines, or crow's feet.
RVNC: 13.25 (-0.04)
Revance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio
GlobeNewswire - Thu Jun 02, 5:12PM CDT
- Portfolio covers diverse and novel indications, compositions and formulations -
RVNC: 13.25 (-0.04)
Revance to Participate in Upcoming Investor Conferences
GlobeNewswire - Tue May 31, 3:05PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming investor conferences.
RVNC: 13.25 (-0.04)
Revance reports 1Q loss
Automated Insights - Mon May 09, 5:48PM CDT
NEWARK, Calif. (AP) _ Revance Therapeutics Inc. (RVNC) on Monday reported a loss of $19.9 million in its first quarter.
RVNC: 13.25 (-0.04)
Revance Releases First Quarter 2016 Results
GlobeNewswire - Mon May 09, 3:06PM CDT
- Completes Enrollment in REALISE 1 Phase 3 Trial for RT001 Topical for Crow's Feet Lines -
RVNC: 13.25 (-0.04)
Revance Therapeutics to Release First Quarter 2016 Financial Results Monday, May 9, 2016
GlobeNewswire - Mon Apr 25, 3:01PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the Company will release first quarter 2016 financial results on Monday, May 9, 2016 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business and pipeline update.
RVNC: 13.25 (-0.04)
Revance Therapeutics Expands Leadership Team, Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development
GlobeNewswire - Mon Mar 14, 6:17PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced a key addition to its leadership team with the appointment of Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development, effective immediately. Dr. Rubio will report to Chief Operating Officer Abhay Joshi, and will lead the company's clinical development team, focusing on further accelerating the advancement of Revance's neurotoxin development programs.
RVNC: 13.25 (-0.04)
Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology
GlobeNewswire - Sat Mar 05, 12:45PM CST
- Findings confirm statistically significantly greater duration of effect for RT002 compared to BOTOX(R) Cosmetic -
RVNC: 13.25 (-0.04)
Axillary Hyperhidrosis Pipeline Review H2 2015
M2 - Tue Feb 02, 5:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/w8hlmc/axillary) has announced the addition of the "Axillary Hyperhidrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Axillary Hyperhidrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Axillary Hyperhidrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Axillary Hyperhidrosis Overview - Therapeutics Development - Pipeline Products for Axillary Hyperhidrosis - Overview - Pipeline Products for Axillary Hyperhidrosis - Comparative Analysis - Axillary Hyperhidrosis - Therapeutics under Development by Companies - Axillary Hyperhidrosis - Therapeutics under Investigation by Universities/Institutes - Axillary Hyperhidrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Axillary Hyperhidrosis - Products under Development by Companies - Axillary Hyperhidrosis - Products under Investigation by Universities/Institutes - Axillary Hyperhidrosis - Companies Involved in Therapeutics Development - Allergan Plc - Brickell Biotech, Inc. - Dermira Inc. - GlaxoSmithKline Plc - Revance Therapeutics, Inc. - TheraVida, Inc For more information visit http://www.researchandmarkets.com/research/w8hlmc/axillary
AGN: 238.28 (-2.31), DERM: 30.27 (-0.64), RVNC: 13.25 (-0.04), GSK: 43.52 (+0.14)
Migraine Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tw7v3m/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Migraine Overview - Therapeutics Development - Pipeline Products for Migraine - Overview - Pipeline Products for Migraine - Comparative Analysis - Migraine - Therapeutics under Development by Companies - Migraine - Therapeutics under Investigation by Universities/Institutes - Migraine - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Migraine - Products under Development by Companies - Migraine - Products under Investigation by Universities/Institutes - Migraine - Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - Alder Biopharmaceuticals Inc. - Allergan Plc - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - Corium International, Inc. - D-Pharm Ltd. - Eli Lilly and Company - iCeutica, Inc. - Impel NeuroPharma, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - Promius Pharma, LLC - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited - TheraJect, Inc. - Trevena, Inc. - Trigemina, Inc. - Vertex Pharmaceuticals Incorporated - Zosano Pharma Corporation For more information visit http://www.researchandmarkets.com/research/tw7v3m/migraine
BDSI: 2.51 (-0.07), TRVN: 7.06 (-0.07), VRTX: 90.10 (+1.14), RDHL: 11.75 (+0.45), ZSAN: 1.12 (unch), AMGN: 160.18 (-0.92), LLY: 79.14 (-0.52), ACOR: 25.57 (-0.64), NKTR: 15.07 (+0.15), AGN: 238.28 (-2.31), CORI: 4.00 (unch), ALDR: 26.88 (-0.12), CLCD: 9.00 (-0.03), MRK: 59.34 (-0.01), TEVA: 50.93 (+0.04), RVNC: 13.25 (-0.04), POZN: 5.94 (-0.43)
The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis
Zacks Equity Research - Zacks Investment Research - Fri Jan 08, 8:30AM CST
The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis
LGND: 126.76 (+0.90), AMGN: 160.18 (-0.92), RVNC: 13.25 (-0.04), ABBV: 64.35 (+0.19), EXEL: 8.15 (unch)
